Abstract:The present study aimed to explore the role of integrin 131 and the relevant signaling pathways in acquired gefitinib resistance in non-small cell lung cancer (NSCLC). The inhibitory effects of gefitinib, with or without LY294002, on cellular proliferation were evaluated by 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide assay. Cell cycle progression and apoptosis were analyzed by flow cytometry, while western blotting was used to evaluate the expression of EGFR, phosphorylated (phospho)-EGFR; protein kinase B (Akt), phospho-Akt, extracellular signal-regulated kinase (Erk) and phospho-Erk. The gene expression profiles of PC9 and PC9/G cells were determined by DNA microarray. Integrin beta 1 was knocked down in PC9/G cells by transiently transfected short interfering RNA (siRNA). A scrambled siRNA sequence was used as a contiol. Apoptosis of transfected cells was determined by Annexin V-phycoerythrin-Cy5/propidium iodide staining. Sequencing products were amplified by nested PCR. The resistant index of PC9/G cells to gefitinib was similar to 138- to 256-fold higher than that of PC9 cells, and this resistance was accompanied by significant increase in integrin 131 expression in PC9/G cells. Knockdown of integrin 131 with short hairpin RNA in PC9/G cells markedly inhibited proliferation and enhanced apoptosis in response to gefitinib, restoring the sensitivity of PC9/G cells gefitinib. Phosphoinositide 3-kinase (PI3K)/Akt activation was observed in PC9/G cells in the presence of gefitinib and the sensitivity of PC9/G cells to gefitinib was also able to be restored by PI3K/Akt pathway inhibitor LY294002. Finally, knockdown of integrin 131 significantly reduced the levels of phospho-Akt. These findings suggest that integrin 131 signaling via the PI3K/Akt pathway may be a significant mechanism underlying gefitinib resistance, and may potentially present an alternative therapeutic target for the treatment of NSCLC unresponsive to EGFR inhibitors.

Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation

Imperatorin increased sensitivity of lung cancer CD133 +cell subsets to gefitinib by down-regulating c-met expression

Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Integrin Β1 Participates in Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

The Role of Up-Regulation of Integrin Β1 in Resistance to Gefitinib in Non-Small Cell Lung Cancer

Integrin Β1-Mediated Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cells Occurs Via the Phosphoinositide 3-Kinase-dependent Pathway.

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Gefitinib-Resistance is Related to Bim Expression in Non-Small Cell Lung Cancer Cell Lines

Β-Catenin Overexpression is Associated with Gefitinib Resistance in Non-Small Cell Lung Cancer Cells.

Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells

Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib

Implication of Epithelial-Mesenchymal Transition in IGF1R-induced Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer

The Mir‑625‑3p/axl Axis Induces Non‑t790m Acquired Resistance to EGFR‑TKI Via Activation of the TGF‑β/Smad Pathway and EMT in EGFR‑mutant Non‑small Cell Lung Cancer.

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells

IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.